Navigation Links
Avandia Raises Heart Risk But Should Stay on Market, FDA Panel Finds
Date:7/15/2010

lex ways than one might have imagined. The panel did the best they could with data that weren't completely conclusive, that suggested an increased risk but didn't make it clear how much that increased risk was," he said.

And he explained, "The majority of the panel didn't feel the increased risk was enough to summarily remove a drug that hundreds of thousands of people are taking successfully."

A second heart expert agreed.

"I didn't think that the evidence was yet compelling enough to withdraw the product from the market," said Dr. Kirk Garratt, clinical director of interventional cardiovascular research at Lenox Hill Hospital in New York City. "It sounds like they're going to add some new warnings regarding the risk, and that seems like an appropriate step."

And such a step will likely decrease the use of Avandia, anyway, Garratt added. "Use went down pretty sharply after criticism started to fly and the presence of new boxed warnings will further depress the prevalence of this product in the marketplace," he said.

But Garratt also said he didn't think the experts' votes would end the controversy over Avandia.

"There is so much dissent within the FDA about the appropriate action to take with this drug that I can't imagine this will be the final world," he said. "Also, we've got an alternative product [Actos] that seems to be essentially as effective at controlling diabetes but hasn't been linked to the cardiovascular risks."

In a statement released after the vote, Dr. Ellen Strahlman, chief medical officer at GlaxoSmithKline, which makes Avandia, said, "Following today's recommendations, we will, of course, continue to work with the FDA in the best interest of diabetes patients ... Patients taking Avandia should speak with their physician about their treatment and any questions they may have regarding the safety of the medicine."

The FDA committee had been meeting intensively since early Tuesday morning, hearing di
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3 4

Related medicine news :

1. FDA Panel Seems Skeptical Over Key Avandia Data
2. FDA Panel Appears Skeptical Over Key Avandia Data
3. Avandia Heart Risks Buried by Drug Company: Report
4. FDA Reviewer Questions Results of Key Avandia Trial
5. Latest Study on Diabetes Drug Avandia Finds No Heart Risks
6. Diabetes Drug Avandia Ups Heart Risk, Reviews Conclude
7. Maher Law Firm Warns Avandia Users - NY Times Reports - FDA Recommends Recall of Avandia
8. FDA: No Decision on Whether to Pull Diabetes Drug Avandia Off the Market
9. FDA Says It Hasnt Decided Whether to Pull Diabetes Drug Avandia Off the Market
10. Remove Diabetes Drug Avandia From Market: FDA Documents
11. Remove Diabetes Drug Avandia From Market: FDA Reports
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Avandia Raises Heart Risk But Should Stay on Market, FDA Panel Finds
(Date:9/18/2014)... Clinical trial report, “Edema Global Clinical ... clinical trial scenario. This report provides elemental information and ... includes an overview of the trial numbers and their ... across the globe. The databook offers a preliminary coverage ... prominence of the sponsors and also provides briefing pertaining ...
(Date:9/18/2014)... London. (PRWEB) September 18, 2014 CD-adapco, ... Aided Engineering software, today announced its new partnership with ... utilizing the CD-adapco simulation tool, STAR-CCM+® in the design ... announced its participation in the 35th America’s Cup taking ... edition of the America’s Cup is sustainability, the set ...
(Date:9/18/2014)... This news release is available in German . ... at Technische Universitt Mnchen have won the ,International ... Hepatitis C Virus., As their prize, the scientists will ... the space station. The project involves crystallizing two proteins ... shuttle bringing these proteins to the International Space Station ...
(Date:9/18/2014)... According to a new market report published by Transparency ... Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020,” ... USD 77607.7 million in 2013 and is expected to grow ... reach an estimated value of USD 115474.9 million in 2020. ... at a rapid pace due to increasing prevalence of end ...
(Date:9/18/2014)... Norfolk, Virginia (PRWEB) September 18, 2014 ... in the START (Smart Teens Accepting Responsibility Today) Internship ... Stacie D. and Darcy C. describe the program as ... women had any idea about what they would be ... to get coffee, do food runs and other mindless ...
Breaking Medicine News(10 mins):Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 2Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 3Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 4Health News:Ben Ainslie Racing Using STAR-CCM+ Simulation Software to Design 35th America’s Cup Racing Boat 2Health News:Hepatitis C virus proteins in space 2Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 2Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 3Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 4Health News:ARDX Internship Helps Students to START on the Right Business Path 2Health News:ARDX Internship Helps Students to START on the Right Business Path 3Health News:ARDX Internship Helps Students to START on the Right Business Path 4
... Hundreds ... HCG and how can it help us? , ... May 13, 2010 -- HCG, or human chorionic gonadotropin, is a natural hormone that is found in ... as energy for both the mom and her developing baby. , , , , ,Now, thanks ...
... ... cut from the USDA-NIFA budget, causing a concern among scientists about how urgent, near-term challenges ... (PRWEB) ... appeal to the U.S. Department of Agriculture (USDA) National Institute of Food and Agriculture (NIFA) ...
... ... InterHealth Canada,s three new Turks and Caicos clinical facilities allowing the islands to provide ... ... Telemedicine Inc, the worldwide leading supplier of telemedicine technology , devices, and application ...
... an increased risk of blindness, yet nearly half of the ... annual eye exam to detect possible problems. But ... problems related to diabetes can help meet the screening need, ... compared the ability of two sets of computer programs to ...
... ... House Appropriations Subcommittee to increase funding to federal programs supporting Meharry and the nation,s ... ... M.D., MPH, MBA, MACP, President & Chief Executive Officer of Meharry Medical ...
... can cause trouble, experts say , WEDNESDAY, May 12 (HealthDay ... implant and maintain could make life better for people who ... , A defibrillator delivers an electric shock to restart a ... implanted in Americans each year. Current models require careful surgery ...
Cached Medicine News:Health News:All About the HCG Drops Diet Program—What it is and Why it Works 2Health News:WSSA Issues Strong Appeal to USDA for Restoration of Funding for Weed Science 2Health News:WSSA Issues Strong Appeal to USDA for Restoration of Funding for Weed Science 3Health News:WSSA Issues Strong Appeal to USDA for Restoration of Funding for Weed Science 4Health News:AMD Global Telemedicine Inc. Chosen by InterHealth Canada as the Telemedicine Solutions Provider for Turks and Caicos Hospital Project 2Health News:AMD Global Telemedicine Inc. Chosen by InterHealth Canada as the Telemedicine Solutions Provider for Turks and Caicos Hospital Project 3Health News:Computers can effectively detect diabetes-related eye problems 2Health News:Computers can effectively detect diabetes-related eye problems 3Health News:Meharry Medical College President Testifies Before the U.S. House of Representatives 2Health News:Meharry Medical College President Testifies Before the U.S. House of Representatives 3Health News:New Implanted Defibrillator May Be Simpler, Safer 2Health News:New Implanted Defibrillator May Be Simpler, Safer 3
(Date:9/18/2014)... , Sept. 18, 2014 MiMedx Group, ... developer, processor and marketer of patent protected regenerative ... announced today that it has entered into a ... MiMedx will provide its dehydrated human amnion/chorion membrane ... non- exclusively on a private label basis. ...
(Date:9/18/2014)... 18, 2014  Halozyme Therapeutics, Inc. (NASDAQ: ... Food and Drug Administration (FDA) has removed the ... PEGPH20 in SWOG,s ongoing Phase 1b/2 clinical trial ... investigational drug PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in ... with metastatic pancreatic adenocarcinoma.  The study will resume ...
(Date:9/18/2014)... -- Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company ... announced today that it has appointed Mr. Christopher ... of Clinical Development. During his extensive career ... successful global clinical operations teams, in the US and ... development of numerous therapeutics and diagnostics across a broad ...
Breaking Medicine Technology:MiMedx Signs Distribution Agreement With Zimmer 2MiMedx Signs Distribution Agreement With Zimmer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2
... (ASX: PGL; Nasdaq: PGLA) today announced additional,data from the ... this,year. This data was presented at the 58th Annual ... Diseases in Boston, USA(1). As the Phase 2 ... data analysis described in this presentation was performed to,evaluate ...
... overall rate of sustained virologic response in ... long-acting interferons in ... Albuferon non-responder study presented at the, Annual Meeting of the American Association for the Study ... ...
Cached Medicine Technology:Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases 2Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases 3Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 2Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 3Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 4Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 5Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 6
... German Craftsmanship have produced the ... world. Ocutek now makes them ... of the coveted Meisterbrief certificate, ... are qualified to become Ocutek ...
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: